OrbiMed’s Pulmonx LUNG Stock Holding History

OrbiMed’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-435,000	Closed	-$7.25M	–	125
2022 Q3	$7.25M	Hold	435,000	–	–	0.13%	96
2022 Q2	$6.4M	Hold	435,000	–	–	0.12%	105
2022 Q1	$10.8M	Hold	435,000	–	–	0.18%	98
2021 Q4	$13.9M	Hold	435,000	–	–	0.18%	103
2021 Q3	$15.7M	Buy	435,000 +310,000	+248%	+$12.2M	0.17%	108
2021 Q2	$5.51M	Hold	125,000	–	–	0.06%	145
2021 Q1	$5.72M	Hold	125,000	–	–	0.05%	137
2020 Q4	$8.63M	Buy	+125,000	New	+$6.12M	0.08%	124

Other funds holding LUNG

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

OrbiMed's LUNG Position: Q4 2022 in Review

OrbiMed sold out of Pulmonx (LUNG) in Q4 2022, closing a stake of 435,000 shares — an estimated $7.25M sold.

OrbiMed first reported a position in LUNG in Q4 2020 and held it in 8 quarters. The position peaked at $15.7M in Q3 2021. 115 funds tracked by Wall St. Rank hold LUNG as of Q4 2022.

OrbiMed reported no remaining Pulmonx position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 435,000 Pulmonx shares in Q4 2022, an estimated $7.25M.
OrbiMed first reported a position in Pulmonx in Q4 2020 and held it in 8 quarters.
OrbiMed's Pulmonx position peaked at $15.7M in Q3 2021.
115 funds tracked by Wall St. Rank held Pulmonx as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.